What OncoC4 does

OncoC4 is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Rockville, Maryland, that develops first-in-class and best-in-class immunotherapy candidates for hard-to-treat cancers and neurodegenerative diseases. The company's scientific approach targets innate and adaptive immune checkpoints — CTLA-4, PD-1/VEGF, CD24, and Siglec — across multiple antibody modalities including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. Its lead asset, gotistobart (BNT316/ONC-392), is a pH-sensitive anti-CTLA-4 antibody co-developed with BioNTech that preserves CTLA-4 recycling while preferentially depleting immunosuppressive tumor T cells; it is in Phase 3 development (PRESERVE-003) for second-line squamous non-small cell lung cancer, with reported 54% reduction in death risk versus docetaxel. The pipeline also includes ONC-841, now in Phase 1/2 for Alzheimer's disease in China, plus earlier-stage PD-1/VEGF, CD24, and Siglec programs. The company operates a lean 11-50 person team with wholly-owned subsidiaries in China (Nanjing, Guangzhou, Beijing) and Australia (Brisbane) to support global clinical execution.

The business model is a clinical development and partnership model typical of pre-commercial biotech. OncoC4 does not currently generate commercial revenue and identifies future income as coming from potential product sales upon regulatory approval or one-time licensing arrangements. The company relies on strategic partnerships for co-development and eventual commercialization — notably with BioNTech for gotistobart and with Bristol Myers Squibb for pumitamig — while funding operations through equity financings, including a nearly $50 million Series B round in October 2025 led by GBA Fund. Customer segments are therapeutic indications rather than paying customers: oncology (immunotherapy-resistant NSCLC, platinum-resistant ovarian cancer, squamous NSCLC) is the primary segment, with neurodegenerative disease (Alzheimer's) as a secondary segment. Value proposition centers on differentiated antibody engineering that may improve efficacy and reduce immune-related adverse events relative to conventional checkpoint inhibitors, supported by FDA Orphan Drug Designation and Phase 3 survival data.

Name

OncoC4

Legal name

OncoC4, Inc.

Website

https://oncoc4.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Short description

OncoC4 is a clinical-stage biopharmaceutical company developing novel immunotherapy antibodies targeting CTLA-4, PD-1/VEGF, CD24, and Siglec pathways for hard-to-treat cancers and neurodegenerative diseases, partnered with BioNTech and Bristol Myers Squibb.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Bispecific & Multispecific Antibodies (HLAAAAAF)

akta.pro secondary industries

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Cancer immunotherapy
• Monoclonal antibodies
• Immune checkpoint inhibitors
• Clinical-stage biopharmaceutical
• Antibody therapeutics

Headquarters

HQ city

Rockville

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pipeline Development and Potential Commercialization: As a clinical-stage biotechnology company, OncoC4 is developing cancer and neurodegenerative disease therapies with multiple candidates in clinical trials. Revenue would be generated through potential future product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

OncoC4 discovers and develops novel biological therapeutics targeting innate and adaptive immune checkpoints—specifically CTLA-4, PD-1/VEGF, CD24, and Siglec pathways—for hard-to-treat cancers and neurodegenerative diseases such as Alzheimer's. The company leverages proprietary pH-sensitive antibody engineering and multiple modalities including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. Its lead clinical candidate, gotistobart (ONC-392/BNT316), is a pH-sensitive anti-CTLA-4 antibody co-developed with BioNTech, with a second candidate ONC-841 advancing in oncology and Alzheimer's disease indications.

Product overview

OncoC4 is a clinical-stage biopharmaceutical company developing first-in-class and best-in-class medicines for hard-to-treat cancer and Alzheimer's disease. The company's product portfolio centers on its lead candidate Gotistobart (ONC-392/BNT316), a pH-sensitive anti-CTLA-4 antibody developed in partnership with BioNTech, currently in late-stage clinical trials for lung and ovarian cancers. Beyond Gotistobart, OncoC4 is advancing ONC-841 for both solid tumors and Alzheimer's disease. The company's therapeutic approach leverages a diverse array of modalities including monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), and antibody-drug conjugates (ADCs), targeting immune checkpoints including CTLA-4, PD-1/VEGF, CD24, and Siglecs.

Differentiator

Problem solved

Functional benefit

Products and services

• Gotistobart (ONC-392/BNT316) A pH-sensitive anti-CTLA-4 monoclonal antibody designed to preserve CTLA-4 recycling while preferentially depleting immunosuppressive T cells within tumors. Co-developed with BioNTech for treatment of immunotherapy-resistant non-small cell lung cancer and other advanced tumors; demonstrated 54% reduction in death risk (HR 0.46) versus standard chemotherapy in Phase 3 squamous NSCLC.
• ONC-841 A therapeutic candidate being developed for solid tumors and Alzheimer's disease, currently in Phase 1/2 clinical trial for Alzheimer's disease following prior development for oncology indications. The candidate leverages Siglec pathway targeting to restore microglial function.

Quantifiable outcome

• Gotistobart demonstrated 54% reduction in death risk (HR 0.46) versus standard chemotherapy in Phase 3 trial for squamous NSCLC
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• BioNTech SEcoreStrategic or Co-development PartnerBioNTech and OncoC4 co-developed gotistobart (BNT316/ONC-392), a pH-sensitive anti-CTLA-4 antibody demonstrating sustained anti-tumor activity and clinically relevant overall survival rates in platinum-resistant ovarian cancer. BioNTech presents clinical data at major conferences including ASCO 2026. Partnership advancing multiple late-stage clinical trials.
• Bristol Myers SquibbcoreStrategic or Co-development PartnerPartnership for development of pumitamig, an immunomodulator candidate. BioNTech highlighted pumitamig data from ROSETTA Lung-02 trial showing encouraging anti-tumor activity in first-line non-small cell lung cancer. Multiple global Phase 3 studies ongoing.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Compugen: Clinical-stage immuno-oncology company developing novel checkpoint-based therapeutics using a computational discovery platform. Comparable to OncoC4 in stage, size, and focus on next-generation immune checkpoint targets for solid tumors.
• Werewolf Therapeutics: Clinical-stage biotech developing conditionally activated immuno-oncology therapeutics, including PREDATOR platform-based INDUKINE molecules. Similar size, clinical-stage profile, and IO focus to OncoC4.
• Shattuck Labs: Clinical-stage immuno-oncology company developing bifunctional fusion proteins and bispecifics targeting TNF superfamily and immune checkpoints. Direct overlap with OncoC4's BsAb modality and checkpoint pipeline.
• Surface Oncology: Clinical-stage immuno-oncology biotech focused on next-generation antibodies targeting innate and adaptive immune checkpoints. Highly comparable in target space (PVRIG, IL-27) and stage to OncoC4.
• Pionyr Immunotherapeutics: Clinical-stage immuno-oncology company developing myeloid-targeting antibodies for solid tumors. Overlaps with OncoC4's innate immune checkpoint approach (e.g., Siglec, CD24 targeting) and clinical-stage profile.

Broad incumbents

• Bristol Myers Squibb: Global pharma with the leading approved anti-CTLA-4 (ipilimumab/Yervoy) and PD-1 (Opdivo) franchises. OncoC4's BMS partnership for pumitamig plus its CTLA-4 ambitions place BMS as both partner and principal incumbent competitor.
• Merck & Co. Owns Keytruda (pembrolizumab), the dominant PD-1 checkpoint inhibitor against which OncoC4's PD-1/VEGF program will compete. Represents the standard-of-care benchmark for OncoC4's IO development.
• Roche: Major IO player with Tecentriq (anti-PD-L1) and broad bispecific antibody pipeline. Comparable commercial and development scope to OncoC4's IO ambitions across multiple checkpoint targets.
• AstraZeneca: Owns Imfinzi (anti-PD-L1) and tremelimumab (anti-CTLA-4), the most direct approved competitor to gotistobart. Comparable dual-checkpoint strategy (PD-1/VEGF parallels Imfinzi+tremelimumab combinations).

Regional players

• Innovent Biologics: Leading Chinese biopharma with marketed PD-1 inhibitor (sintilimab) and broad oncology biologics pipeline including bispecifics. Comparable to OncoC4 in bispecific antibody development and Chinese clinical footprint via OncoC4's Nanjing/Guangzhou/Beijing subsidiaries.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/oncoc4

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OncoC4